Description
Data Available
To access this data, please log into DSS and submit an application.
Within the application, add this dataset (accession NG00127) in the “Choose a Dataset” section.
Once approved, you will be able to log in and access the data within the DARM portal.
Description
The goal of WU350 cohort is to address the many complexities of the COVID-19 pandemic. Among the 332 COVID-19 cases, ~90% were symptomatic patients, 93.7% were hospitalized, 46.7% with ICU admission, 24.7% on ventilation, and 19.0% died due to COVID-19 (82 ventilated and 63 died; 44 of the deceased had been ventilated prior to death). COVID-19 patients were 59 years old on average, 58.7% men and 67.8% of African American ancestry.
A total of 150 age-, sex-, and race-matched non-COVID-19 samples were used as controls. Controls samples were collected from the Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight-ADRC), at Washington University in St. Louis. The Knight-ADRC is one of 30 ADRCs funded by NIH. The goal of this collaborative research effort is to advance AD research with the ultimate goal of treatment or prevention of AD.
From the 482 individuals, peripheral blood was collected, and plasma was isolated by centrifuge and stored at -80⁰C. The proteomic data in plasma was measured using SomaScan v4.1 7K, a multiplexed, single-stranded DNA aptamer-based platform from SomaLogic (Boulder, CO). Instead of physical units, the readout in relative fluorescent units (RFU) was used to report the protein concentration targeted by 7,055 modified aptamers.
Additional information can be found on the websites:
https://neurogenomics.wustl.edu/
https://covid.proteomics.wustl.edu/
Sample Summary per Data Type
Sample Set | Accession | Data Type | Number of Samples |
---|---|---|---|
Knight ADRC & WU350 | snd10038 | Proteomics | 482 |
Available Filesets
Fileset | Accession | Latest Release | Description |
---|---|---|---|
COVID19 - Proteomic and Phenotypic Data | fsa000034 | NG00128.v1 | Proteomic and Phenotypic Data |
View the File Manifest for a full list of files released in this dataset.
Subject Information
COVID-19 cases (N=350) who presented with respiratory illness symptoms and had a physician-ordered positive SARS-CoV-2 test performed at the Barnes Jewish Hospital between 26 March 2020 and 28 August 2020 (Washington University 350 (WU350) cohort). Knight-ADRC cohort collects cognitive data, plasma, CSF and imaging to study the risk factors for Alzheimer’s disease. 150 age, sex and race matched Knight-ADRC cohort participants were used as COVID-19 Controls.
Sample Set | Accession | Number of Subjects |
---|---|---|
Knight ADRC & WU350 | snd10038 | 482 |
Related Studies
Consent Levels
Consent Level | Number of Subjects |
---|---|
DS-ADRD-IRB-PUB | 482 |
Visit the Data Use Limitations page for definitions of the consent levels above.
Acknowledgement
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
Use the study-specific acknowledgement statements below (as applicable):
For investigators using any data from this dataset:
Please cite/reference the use of NIAGADS data by including the accession NG00128.
For investigators using KnightADRC & WU350 (sa000026) data:
Funding: This work was supported by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), and R01AG057777 (OH)), and the Chuck Zuckerberg Initiative (CZI).
The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). O.H. is an Archer Foundation Research Scientist.
This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
This study utilized samples obtained from the Washington University School of Medicine’s COVID-19 biorepository, which is supported by: the Barnes-Jewish Hospital Foundation; the Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the view of the NIH.
Related Publications
Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways. iScience. 2022.